- Description
 - Additional
 
Description
Details
Description:Mouse monoclonal antibody to human platelet membrane glycoprotein IIb/IIIa (GP IIb/IIIa)
Purification:Protein G affinity purified
Product Type: Primary antibody
Target Protein:Human platelet membrane glycoprotein IIb/IIIa
Immunogen:Human platelet suspension
Fusion Myeloma:Sp2/0-Ag14
Specificity:The mAb reacts with human platelet.
Species Reacitvity:Human, others not tested
Host / Isotype:Mouse, IgG2b Kappa
Formulation:Lyophilized from a solution in 0.01M PBS, pH 7.2
Reconstitution:Double distilled water is recommended to adjust the final concentration to 1.00mg/mL.
Storage: Store at -20oC
Research Area:Hematology, blood coagulation
Background:
Human platelet membrane glycoprotein Glycoprotein IIb/IIIa (GP IIb/IIIa) is a dominate receptor on the platelet membrane with very high molecular weight (>200kDa). After the platelet is activated, the GP IIb/IIIa receptor complex changes conformation and binds to fibrinogen in blood circulation with high affinity. The activation of platelets is initiated locally when the endothelial layer is wounded and the platelets are exposed to the collagen underneath the endothelium. The fibrinogen aggregates with platelets when binding to the GP IIb/IIIa receptor on platelets, thus primary haemostasis (Platelet clot) is formed.
Application:
ELISA:The mAb is reactive to platelet coated ELISA plate.
Other applications have not been evaluated.
References:
If research is published using this product, please inform Anogen in order to cite the reference on this datasheet. Anogen will provide one unit of product in the same category as gratitude.
Additional
Additional Information
| Product Specificity | mAb anti-Human GP IIb/IIIa, 291 | 
|---|---|
| Application | EIA | 
| Size | 0.1 mg | 
ebiomall.com
    
                
        
        
        
        >
                                                    >
                                                    >
                                                    >
                                                    >
                                                    >
                                                    >
                                                    >
                                                    >
                                                    >
                                                    >
                                                    >
                                                    2006年,由蔡宗建(董事长)和池元(首席执行官),于福建福州(总部)成立“福州天盟数码有限公司”。
2009年,于新加坡成立“IGG Singapore Pte. Ltd.”(前身为“Skyunion Pte. Ltd.”)。
IGG主要专注于海外运营,截至2011年,IGG将20多款国产端游及页游推向海外市场,在全球拥有2000多万注册用户。鉴于在海外市场取得的良好成绩,IGG相继开发了《百年战争》、《泰坦战争》,准备凭借这两款产品进军国内市场。但国内的玩家对这两款网游并不买账,在国内表现不佳,几乎让蔡宗建赔光了老本,2011年底,IGG连员工的年终奖都没有发。由于这次惨痛的失败,蔡宗建不得不放弃国内市场。
2012年,IGG与facebook合作,推出了《Galaxy Online2》(星际文明2)。
2013年IGG投入了移动游戏市场,截至到2013年已经推出了9款手机游戏,截至2013年5月31日,IGG手机游戏日活跃用户的平均收益为0.08美元,平均日活跃用户为31.7万人。
2013年10月18日,蔡宗建带领下的IGG在港交所成功上市,公司市值达40.2亿港元。向左转|向右转
文章原文链接http://www.jbc.org/content/282/23/16776.long
2-IgM也是一种特异性感染指标,但在人体内持续时间不长(有时是30天更短),往往是传染病的近期感染指标。呈阴性是指:你近期没有感染过结核杆菌。
IgM是免疫球蛋白M(Immunoglobulin M,IgM)的缩写。根据结构的不同将免疫球蛋白分为五种,IgM是人的免疫球蛋白之一,其他还有lgA、lgG、IgD和lgE。

                                    
                    